-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 23rd Stone Pharmaceuticals released its first three quarters 2020 results.
report showed that Stone Pharmaceuticals recorded revenue of RMB19,215 million in the first three quarters, up 14.6% YoY, and investment in research and development of RMB2,266 million, up 50.87 percent YoY from RMB1,502 million in the same period last year, accounting for 14.4% of the revenue of the drug.
since the new crown epidemic was gradually controlled in China, hospital visits and marketing activities have been revived, the overall operation of stone medicine has generally returned to normal.
to give full play to the policy advantages of the winning varieties, quickly occupy the hospital market and expand the market space of varieties.
newly approved product Eugene (Hydrochloric Loxitin intestinal capsule) was successfully launched in September, enriching the Group's portfolio in the field of neurological disorders.
results showed that Shi Pharmaceuticals' business revenue was 157.13, up 17.4% year-on-year.
's main products include Umbipu (butyl benzene softgels and sodium butyl chloride injections), Olainen (Orasitan capsules and injections of oxytoin) and Enci (Plaxo hydrochloride tablets).
period, the two focus areas had better incomes.
of 5,987 million yuan, an increase of 9.6% year-on-year.
ennising sales revenue increased by 32.1 per cent.
anti-tumor products include polymetin (hydrochloric acid dorobi star lipid body injection), Zin yuli (polyglycol recombinant human granulocyte stimulation factor injection) and ker ailment (injection with yew alcohol albumin binding type).
period, anti-tumor products recorded sales revenue of RMB4,717 million, an increase of 35.4% YoY.
sales revenue of Domesin, Zinyouli and Que Aili increased by 36.3%, 45.2% and 33.1%, respectively.
research and development, the stone drug obtained devassaban tablets, Monrust sodium tablets, Monrust sodium chewing tablets, mendongine birdine injections, injectable boron zomi, celexib capsules, Domestic drug registration approvals for Acapo sugar tablets, hydrochloric acid meth tablets and hydrochloric acid loxitin intestinal capsules; 18 varieties (25 product regulations) were evaluated by the same as the quality and efficacy of generic drugs.
currently in research projects more than 300 items, including small molecule innovation drugs more than 40 items, large molecule innovation drugs more than 50 items, more than 20 new preparations.
Currently, 28 drugs are in the registration review phase, 42 products are undergoing clinical trials (including 31 innovative drugs and 11 new agents), 9 products are undergoing bioethic trials, and 2 products are in clinical approval.
the next three years, Shi medicine is expected to be listed more than 50 new products, of which the market space is expected to exceed 1 billion yuan of heavy-weight varieties will be no less than 15.